Form 4: BIODESIX CFO Sells Shares for Tax Obligations

BIODESIX CFO Robin Harper Cowie sold 988 shares of common stock to cover tax obligations following the vesting of restricted stock units.

Summary

• CFO Robin Harper Cowie acquired 3,157 shares of BIODESIX INC common stock on August 12, 2025, through the vesting of Restricted Stock Units (RSUs).
• On August 13, 2025, Cowie sold 988 shares of common stock at a weighted average price of $0.4163 per share.
• The sale was conducted automatically to cover tax obligations associated with the RSU vesting.
• Following these transactions, Cowie directly beneficially owns 250,794 shares of common stock.
• Cowie also holds 6,313 Restricted Stock Units, which vest in sixteen successive quarterly installments from February 8, 2022.

Sentiment

Score: 6

Explanation: The filing indicates a routine executive compensation event (RSU vesting) followed by an expected tax-related sale. It's neutral to slightly positive as it shows continued executive incentive alignment, with no negative implications for company operations or strategy.

Positives

• Vesting of 3,157 Restricted Stock Units indicates continued compensation and retention of a key executive.
• The RSU vesting schedule extends over sixteen quarterly installments, aligning executive incentives with long-term company performance.

Negatives

• Sale of 988 shares, although for tax purposes, reduces the direct beneficial ownership of the CFO by a small amount.

Future Outlook

NA

Management Comments

• These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
• The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person.

Industry Context

This filing is a routine insider transaction related to executive compensation and tax obligations, not indicative of broader industry trends.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting, but the sale is tax-related and not a discretionary sale indicating lack of confidence. Overall, minimal direct impact.
• Employees: The vesting of RSUs is a standard part of executive compensation, which can be seen as positive for employee retention and morale.

Next Steps

• Continued vesting of remaining 6,313 Restricted Stock Units in successive quarterly installments.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. Such transactions are common and do not typically signal a change in the company's fundamental outlook or the executive's confidence. There are no new material financial or operational insights provided that would warrant a change in investment stance. Therefore, a 'hold' recommendation is appropriate as the filing does not present new information to alter an existing investment thesis.

Keywords

BIODESIX, BDSX, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, CFO, Robin Harper Cowie, Executive Compensation, Tax Obligations